Further combination of CuP/Er with an anti‐PD‐L1 antibody (αPD‐L1) potently regresses tumors and prevents tumor metastasis via synergizing ICD by CuP/Er and reinvigoration of T cells by ICB.[54, 55, 56] Our findings suggest the potential of utilizing Cu ions as an anticancer agent to overcome resistance to conventional cancer therapy. Here, CD274 is linked to cancer.